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Cancer is the third most frequent cause of death in children in Brazil. Early diagnosis and medical advances have
significantly improved treatment outcomes, which has resulted in higher survival rates and the management of
late side effects has become increasingly important in caring for these patients. Dental abnormalities are
commonly observed as late effects of antineoplastic therapy in the oral cavity. The incidence and severity of the
dental abnormalities depend on the child’s age at diagnosis and the type of chemotherapeutic agent used, as
well as the irradiation dose and area. The treatment duration and aggressivity should also be considered.
Disturbances in dental development are characterized by changes in shape, number and root development.
Enamel anomalies, such as discoloration, opacities and hypoplasia are also observed in these patients. When
severe, these abnormalities can cause functional and esthetic sequelae that have an impact on the children’s
and adolescents’ quality of life. General dentists and pediatric dentists should understand these dental
abnormalities and how to identify them aiming for early diagnosis and appropriate treatment.
KEYWORDS: Tooth Abnormalities; Drug/Radiotherapy; Cancer; Child.
Carrillo CM, Correˆa FN, Lopes NN, Fava M, Filho VO. Dental anomalies in children submitted to antineoplastic therapy. Clinics. 2014;69(6):433-
437.
Received for publication on November 6, 2013; Accepted for publication on November 26, 2013
E-mail: marcelo.fava@uol.com.br
Tel.: 55 11 2661-8880
& INTRODUCTION
Cancer is the third most frequent cause of death in children
in Brazil, after accidents and violence (1). The survival rates
of childhood cancer have significantly increased due to early
diagnosis and advances in medicine, so attention has become
focused on the late effects of antineoplastic therapy.
Dental anomalies are among the most common long-term
side effects of childhood cancer therapy in the oral cavity.
They may lead to anatomic, functional and aesthetic
sequelae, and severe abnormalities can cause malocclusion,
affect facial development and impact the quality of life (2).
The incidence and severity of dental abnormalities
depend on the age at the diagnosis and the type of
chemotherapeutic agent used, as well as the irradiation
dose and area (3,4). The duration and severity of anti-
neoplastic treatment should also be considered. Dental
development disturbances are characterized by changes in
shape, size, number and root development.
General dentists and pediatric dentists provide oral care
to childhood cancer survivors. Therefore, it is imperative
that they familiarize themselves with the adverse effects of
cancer therapy.
Epidemiology of childhood cancer
More than 9,000 new childhood cancers are diagnosed
annually in Brazil. Cancer is the third leading cause of death in
the 1- to 19-year-old age group, behind accidents and violence.
Childhood cancer requires special care for not only the
psychological and social effects but also because of the high
costs involved in diagnosis, treatment and long-term follow-
up (5). The types of cancers that affect children younger
than 15 years old are distinct from those that affect adults.
The most prevalent childhood cancers are leukemias,
lymphomas, central nervous system tumors, rhabdomyo-
sarcoma, Wilms’ tumor, retinoblastoma and bone tumors;
while in adults, lung, stomach, intestine, prostate and breast
cancer predominate (6). The literature reports that during
childhood, acute lymphocytic leukemia (ALL) is the most
common malignancy, representing 24% of all childhood
malignant neoplasias (7-9) and 75% of all childhood
leukemias (10). The 0- to 4-year-old age group is cited as
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the age group most frequently affected by cancers; however,
lymphomas, carcinomas and bone tumors are the most
prevalent cancers in the 10-14-year-old age group (11,12). In
Brazil, leukemia predominates in the 1- to 4-year-old age
group (31.6%); lymphoma is dominant in the 15- to 18-year-
old age group (35.6%), and central nervous system tumors
have a similar prevalence (26%) in all patients younger than
14 years old (1 to 4, 5 to 9, and 10 to 14 years old)(1). With
regard to gender, related studies agree that general tumors,
leukemias, lymphomas and central nervous system tumors
are more prevalent in males than in females (5).
Late effects of childhood cancer therapy
With the increasing number of childhood cancer survi-
vors comes a high incidence of adverse effects because of
more aggressive treatments protocols. Therefore, increasing
focus has been directed toward the late sequelae of
treatment modalities.
The combination of surgery, chemotherapy and radio-
therapy is extremely effective not only in prolonging life but
also in obtaining significant cure rates in many types of
childhood cancer (13). In Brazil, the survival rates range
from 70 to 80% in some types of childhood cancer, such as
ALL (1).According to Dickerman (2007)(14), the number of
long-term survivors of childhood cancer continues to
increase and approximately 75% will have a chronic health
problem resulting from the cancer therapy, whereas 40%
will experience a severe, disabling, or life-threatening
condition or death caused by a chronic condition.
A variety of late effects of childhood cancer therapy can
be noted as malignant late effects (secondary cancer) and
nonmalignant late effects, in which many organs can be
affected, including the oral cavity (13,14)(Table 1).
Late effects of treatment in the oral cavity
Complications resulting from the cancer itself and from
its treatment frequently affect the mouth. Chemotherapy
and head and neck radiotherapy mainly affect developing
tissues, such as teeth and oral soft tissues (15). Generally,
many therapeutic modalities are used to treat childhood
cancer. Chemotherapy and radiotherapy are often com-
bined, making it difficult to later distinguish which
treatment modality causes which effects (16). Oral late
effects of cancer therapy are clinically significant because of
the sequelae they can cause, which may interfere with the
quality of life. The most commonly observed late effects of
head and neck radiotherapy therapy include xerostomia,
trismus, bone alterations that can cause osteoradionecrosis
and craniofacial and dental anomalies (17-19). Dental
anomalies are also caused by chemotherapy; the main late
effects of this therapy are in the mouth (3,16,20).
Dental anomalies in children submitted to
antineoplastic therapy
Antineoplastic therapy can cause disturbances in tooth
eruption and development. The exact molecular mechan-
isms of antineoplastic therapy that result in dental anoma-
lies remain unknown (21,22).
The lack of specificity of both chemotherapeutic agents
and radiation therapy in terms of differentiating neoplastic
cells from metabolically active normal cells might result in
dental and facial development abnormalities (3). The
Table 1 - Prevalence of dental anomalies in childhood cancer survivors.
Authors N Diagnosis
Gender
F M
Mean
age Dental anomalies
Hypoplasia Microdontia Hypodontia Taurodontia
Tapered
roots Blunted roots
Rosenberg et al. 1987 17 ALL _ _ 7.2 _ _ _ _ 13
76%
5
29%
Pajari et al. 1988 34 Various tumors 19 18 5.7 32
94%
_ _ _ _ _
Dahllof et al. 1988 16 BMT 7 9 7.1 4
25%
3
19%
_ _ 14
88%
5
31%
Sonis et al. 1990 97 ALL 61 36 _ 27
28%
21
22%
5
5%
_ 85
88%
60
62%
Nunn et al. 1991 52 ALL+lympho-ma 30 22 6.7 14
27%
14
27%
8
15%
14
27%
14
27%
14
27%
Pajari et al. 1995 45 ALL 25 20 5.4 40
95%
_ _ _ _ _
Kaste et al. 1995 22 Rhabdomyo-
sarcoma
12 10 5.1 _ 5
23%
11
50%
_ _ 13
59%
Kaste et al. 1997 426 ALL 204 259 4.8 _ 80
19%
36
9%
25
6%
_ 103
24%
Nasmann et al. 1997 16 BMT+TBI 9 7 6.3 7
44%
12
75%
9
56%
_ 15
94%
11
69%
52 BMT no TBI 23 29 5.1 7
13%
7
13%
11
21%
_ 10
19%
4
8%
Kaste et al. 1998 52 Neuroblastoma 9 33 0.0 9
17%
20
38%
9
17%
_ _ 9
17%
Aspalan et al. 1999 30 Lymphoma 7 23 _ 14
47%
_ 15
50%
_ 9
30%
2
7%
Minicucci et al. 2003 76 ALL 33 43 5.1 25
39%
28
44%
_ _ _ _
Lopes et al. 2006 137 Various tumors 79 58 5.6 _ 9
7%
8
6%
19
14%
2
2%
5
4%
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severity of these effects on dentofacial structures was found
to be related to the stage of tooth histogenesis, age at
diagnosis, type of treatment performed and irradiation dose
area (3,21). Studies (3,4,16,23-26) have shown a direct
relationship between the severity and prevalence of dental
anomalies and age at diagnosis, which is related to
odontogenesis stage. Children treated before 5 years of
age had the most severe dental defects, suggesting that
immature teeth were at greater risk for developmental
disturbances than mature teeth (3). With the increased life
expectancy of patients younger than 5 years old, it is
important to study late dental effects in children who
undergo cancer treatment at such an early age (16).
Radiotherapy can cause disturbances in dental development
in children; however, the minimal radiation dose necessary
to cause changes in dental development is unknown.
According to Carpenter (27) and Dury (28), 1,000 cGy is
sufficient to cause permanent damage to mature amelo-
blasts and 3,000 cGy is sufficient to arrest dental develop-
ment. However, Fromm et al. (29) and Goho (2) identified
alterations in dental development after 400 cGy dose.
Many authors (16,23,24,30) have reported a higher
prevalence of (and more severe) dental anomalies in
children submitted to head and neck radiotherapy and total
body irradiation combined with chemotherapy compared to
children submitted to only chemotherapy. Raney et al. (31)
and Paulino et al. (32) reported that 75-100% of patients
submitted to radiotherapy presented light to mild hard and
soft tissue damage resulting from irradiation.
The extent and severity of the defects is related to the
radiation type and dose, the age of the patient, irradiation
area, degree of tissue hypovascularity and hypocellularity,
reparative capacity of epithelial cells and associated
chemotherapy (31,33-35). Animal studies (36,37) have
shown dental development disturbances induced by vin-
cristine, vinblastine, doxorubicin and cyclophosphamide.
The extent of dental abnormalities attributed to chemother-
apy depends on many factors, such as the type of
chemotherapeutic agent used, half-life of the drug and
number of cells in susceptible phases of the cell cycle (37). In
addition, the combination of several agents in chemother-
apy protocols, often combined with radiation therapy,
makes it difficult to attribute anomalies in odontogenesis
to any single agent or therapy in these cases and to
determine how they interfere in cellular physiology (37).
Depending on the odontogenesis stage, certain types of
anomalies can be observed (38). Therefore, detailed knowl-
edge of tooth development by dental professionals is
fundamental in interpreting the timing and nature of dental
developmental anomalies and consequently correlating
them to the age at which the event occurred. In patients
submitted to antineoplastic therapy, this correlation is easily
observed, reinforcing the premise that dental development
represents a real biological milestone in health and illness as
well as in the relationship between the mouth and many
diseases and their manifestations and treatments.
Antineoplastic therapies that affect the cells involved in
odontogenesis may cause changes in tooth enamel and root
development, premature apex closure, dental development
delay or retained teeth (3,16,21,24,26). Dental anomalies of
shape (microdontia, macrodontia and taurodontia) and
number (hypodontia), enamel defects (discolorations and
hypoplasia) and root formation disturbances (blunted root,
tapered root and root development delay) have been
described in many studies (3,16,24,26,39). Other anomalies,
such as supernumerary teeth, have also been detected
(24,26). Developmental defects of the enamel organ are well
documented in the scientific literature. Enamel hypoplasias
and discolorations are the most frequent dental defects from
cytotoxic drugs (29,30,37,40). Children treated for ALL seem
to be more severely affected and this result may be reflected
in the longer duration of therapy, which leads to a greater
risk of affecting the developing ameloblasts (24,41,42).
Disturbances in dental morphology induced by high-dose
chemotherapy and total body irradiation in patients have
been shown in many histologic studies. These studies have
also shown that radiation therapy induces both quantitative
and qualitative changes in enamel and dentin during tooth
formation, whereas chemotherapy induces mostly qualita-
tive disturbances (24,42). Microdontia is frequently detected
in long-term childhood cancer survivors. Several studies
have reported a prevalence of microdontia ranging from 22-
78% in this population (3,43,44). Clinically, hypodontia and
microdontia have great importance because they can cause
spacing and movement of teeth, resulting in poor dental
Figure 1 - Panoramic radiograph of a 2-year-old patient at
diagnosis who was submitted to chemotherapy and 1,800 cGy
irradiation. Note microdontia of the lower left premolars and
second permanent molar.
Figure 2 - Panoramic radiograph of a 7-year-old patient at
diagnosis who was submitted to chemotherapy and 2,100 cGy
irradiation. Note agenesi of the lower right second premolar,
taurodontism of the first permanent molars and microdontia of
the upper and lower left premolars.
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alignment and malocclusion (45) (Figure 1).Intensive and
repetitive chemotherapy during initial hard tissue formation
can cause hypodontia (39,42), which consists of the absence
of one or more teeth. It is caused by disturbances in the first
periods of the tooth vital cycle because of the failure of the
dental lamina and tooth bud development processes or
because of impairment of the cellular multiplication that
promotes the development of these buds (proliferation
stage)(38).
For antineoplastic therapy to result in dental agenesis, it
must destroy the cells programmed to form a tooth or to
affect the signaling systems between the tissues in a tooth
bud and prevent calcification (43). Some studies have
reported a prevalence of hypodontia associated with antic-
ancer therapy ranging from 6 to 44% (16,23,25,44). The
effects of cancer treatment in the later stages of tooth
formation are characterized by disturbed root development
(43). The first signs of root development in permanent teeth
are observed on panoramic radiographs beginning approxi-
mately at age 3 years (central incisors and permanent first
molars) to age 7.5 years (permanent second molars) (43) and
root formation is completed after the tooth has erupted into
the oral cavity (46). Changes in odontoblast activity caused
by abnormal secretory functioning of the dentin micro-
tubules and complex changes in inter- and intracellular
relationships can produce shortened, tapered and blunted
roots (42) (Figure 3).
Root development disturbances, such as arrested root
development with short V-shaped roots, arrested root
development with premature apical closure, blunted roots
and anomalies in root number have been reported in
patients treated with high-dose chemotherapy and radio-
therapy (3). Repeated high-dose chemotherapy can result in
root agenesis (42).
Another dental anomaly that is frequently detected in
these patients is taurodontia (Figure 2), which is character-
ized by an enlarged pulp chamber, apical displacement of
the pulpal floor and no constriction at the level of the
cementoenamel junction (47), which is caused by the failure
of Hertwig’s epithelial sheath diaphragm to invaginate at
the proper horizontal level (48). This abnormality usually
affects permanent molar teeth, but it can also be observed in
premolars and primary molar teeth and can become a
challenge when endodontic treatment is needed, particu-
larly because of its anatomy (45). In the dental literature, its
prevalence in children treated for childhood cancer varies
from 6% to 26% (16,45,46).
Many studies have shown differences in the prevalence of
dental anomalies in long-term survivors of childhood
cancer, most likely because of the type of tumor studied,
the chemotherapy protocol used and the age of the study
population, as well as associated body and/or head and
neck irradiation and different assessment methodologies.
Unfortunately, few studies in the scientific literature that
have described the prevalence of dental anomalies in
healthy children in the Brazilian population. These studies
are essential as a comparative measure not only for children
submitted to antineoplastic therapy but also for children
who present other chronic diseases that affect dental
development. However, several studies have demonstrated
a high prevalence of dental anomalies in children submitted
to cancer therapy compared to healthy children (16,23-
26,45,49).
Children submitted to antineoplastic treatment present
several late effects in many organs and systems, including
the oral cavity; these effects are caused by anticancer
treatments. Dental abnormalities are the most frequent
sequelae of therapy for childhood cancer; these abnormal-
ities include microdontia, hypodontia and enamel and root
development disturbances. These abnormalities can cause
malocclusion and affect facial development, consequently
impacting quality of life. Children who are treated at young
ages appear to be more severely affected than children who
are treated later; additionally, radiotherapy seems to cause
more extensive and severe dental defects compared to
chemotherapy. Considering these factors, general and
pediatric dentists should become familiarize themselves
with these late effects, aiming for early diagnosis, proper
dental care and, consequently, improved quality of life for
this increasingly large group of children.
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